SAB Biotherapeutics Announces Clinical Partnership With Naval Medical Research Center To Advance Potential Influenza Treatment
Portfolio Pulse from Benzinga Newsdesk
SAB Biotherapeutics, Inc. (SABS) announced a clinical partnership with the Naval Medical Research Center (NMRC) to advance SAB-176, a potential influenza treatment. The partnership, supported by the Henry Jackson Foundation, will conduct a pharmacokinetic, safety, and tolerability study of SAB-176 in healthy volunteers. SAB-176, developed using SAB's DiversitAb platform, targets influenza A and B and has received Breakthrough Therapy and Fast Track Designations from the FDA. This study marks the first intramuscular administration trial of a DiversitAb platform product.
March 25, 2024 | 2:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SAB Biotherapeutics announced a partnership with NMRC to advance SAB-176, a potential influenza treatment, marking a significant step in its clinical development. The study, supported by the Henry Jackson Foundation, will evaluate the safety and tolerability of SAB-176, which has received FDA Breakthrough Therapy and Fast Track Designations.
The partnership with NMRC and the initiation of a new study for SAB-176 could significantly enhance SAB Biotherapeutics' profile in the biopharmaceutical industry. The FDA's Breakthrough Therapy and Fast Track Designations for SAB-176 underscore its potential efficacy and importance in treating influenza, a disease with substantial morbidity and mortality. This development is likely to be viewed positively by investors, potentially leading to a short-term increase in SABS's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100